Sat, Jul 12, 2014, 12:30 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Amicus Therapeutics, Inc. (FOLD) Message Board

  • marselluswa11ace marselluswa11ace Jan 1, 2013 6:26 AM Flag

    Re: Happy New Years!

    Amicus Therapeutics Inc (FOLD)

    Amicus Therapeutics lost over half of its market value since December 20th after the company announced that Phase 3 global registration study of investigational oral migalastat HCl monotherapy in males and females with Fabry disease who had genetic mutations identified as amenable to migalastat HCl in a cell-based assay results have been failed.

    We think that FOLD stock found a bottom and ready to bounce back up on the following reasons:

    The U.S. Food and Drug Administration agreed to consider the 12-month efficacy and safety data oral migalastat HCl monotherapy versus failed 6-month data

    These 12-month data results expected to be available in the first half of 2013

    More from pipeline: Amicus’s Phase II Trial of AT2220 drug in the treatment of Pompe Disease that has been well-tolerated and demonstrated no related adverse events

    More from pipeline: Amicus’s preclinical AT2101 and AT3375 drug studies for the treatment of Gaucher Disease and the Gaucher-Parkinson’s Link

    Amicus is a “cash-rich” company with $100M cash/hands versus almost no debt

    FOLD stock is heavily shorted (18 percent of float is shorted) and short squeeze to be expected on any positive company’s updates

    *****************************************************************************************************************

    JPMorgan Chase Lowers Price Target on Amicus Therapeutics (FOLD)
    December 20th, 2012 - 0 comments - Filed Under - by Stacy Sanders
    JPMorgan Chase lowered their price target on shares of Amicus Therapeutics (NASDAQ: FOLD) from $9.00 to $5.00 in a research note issued on Thursday. The firm currently has an “overweight” rating on the stock.

    Other equities research analysts have also recently issued reports about the stock. Analysts at Leerink Swann cut their price target on shares of Amicus Therapeutics from $9.00 to $5.00 in a research note to investors on Thursday. They now have an “outperform” rating on the stock. Separately, analysts at Capstone downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note to investors on Thursday. They now have a $3.00 price target on the stock. Finally, analysts at Canaccord Genuity cut their price target on shares of Amicus Therapeutics from $11.00 to $6.00 in a research note to investors on Thursday. They now have a “buy” rating on the stock.

    Sentiment: Strong Buy

 
FOLD
3.96+0.10(+2.59%)Jul 11 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Potbelly Corporation
NasdaqGSFri, Jul 11, 2014 4:00 PM EDT
ACI Worldwide, Inc.
NasdaqGSFri, Jul 11, 2014 4:00 PM EDT